as on September 18, 2025 at 1:29 am IST
Day's Low
Day's High
2.88%
Downside
2.16%
Upside
52 Week's Low
52 Week's High
73.73%
Downside
2.16%
Upside
Check Lineage Cell Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
$315.1M
EPS (TTM)
-0.1917
Dividend Yield
0.00%
Quarterly Earnings Growth YOY
0.00%
PE Ratio (TTM)
-6.85
Industry PE ratio
0P/B Ratio
0PEG Ratio
0EBITDA
-19.8M
Revenue (TTM)
10.9M
Profit Margin
0.00%
Return On Equity TTM
23559300.00%
Track how Lineage Cell Therapeutics Inc P/E has moved over time to understand its valuation trends.
Lineage Cell Therapeutics Inc in the last 5 years
Lowest (0.00x)
September 17, 2025
Industry (0.00x)
September 17, 2025
Today (-6.85x)
September 17, 2025
Highest (0.00x)
September 17, 2025
Today’s Price to Earnings Ratio: -6.85x
Compare market cap, revenue, PE, and other key metrics of Lineage Cell Therapeutics Inc with its industry peers.
Company | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin % |
---|---|---|---|---|---|
BUY | $315.1M | 23.85% | -6.85 | 0.00% | |
BUY | $60.5B | 252.04% | -505.15 | -12.96% | |
NA | $39.0B | NA | NA | -3.89% | |
BUY | $100.3B | 44.17% | 27.85 | 31.86% | |
BUY | $59.6B | 1.78% | 14.1 | 31.37% |
The Lineage Cell Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.
*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.
Investment Value
₹1,00,000
Lineage Cell Therapeutics Inc investment value today
Current value as on today
₹1,57,346
Returns
₹57,346
(+57.35%)
Returns from Lineage Cell Therapeutics Inc Stock
₹52,747 (+52.75%)
Dollar Returns*
₹4,598 (+4.6%)
Based on 12 analysts
83.33%
Buy
16.67%
Hold
0.00%
Sell
Based on 12 analysts, 83.33% of analysts recommend a 'BUY' rating for Lineage Cell Therapeutics Inc. Average target price of $4.17
Get share price movements and forecasts by analysts on Lineage Cell Therapeutics Inc.
What analysts predicted
66.67%UPSIDE
Target Price
$4.17
Current Price
$1.39
Analyzed by
12 Analysts
Target
$4.17
Lineage Cell Therapeutics Inc target price $4.17, a slight upside of 66.67% compared to current price of $1.39. According to 12 analysts rating.
Search interest for Lineage Cell Therapeutics Inc Stock has decreased by -17% in the last 30 days, reflecting a downward trend in search activity.
Time period: to
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
All numbers in Millions USD
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 2 quarters, 1.50M → 2.76M (in $), with an average increase of 45.7% per quarter
Price Rise
In the last 7 days, LCTX stock has moved up by 14.0%
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.1% return, outperforming this stock by 16.6%
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.5% return, outperforming this stock by 109.5%
Profit Down
Netprofit is down for the last 4 quarters, -3.03M → -30.46M (in $), with an average decrease of 223.5% per quarter
Organisation | Lineage Cell Therapeutics Inc |
Headquarters | 2173 Salk Avenue, Carlsbad, CA, United States, 92008 |
Industry | Health Technology |
CEO | Mr. Brian M. Culley M.A., M.B.A. |
E-voting on shares | Click here to vote |
Name | Title |
---|---|
Ms. Alexandra Hernandez | Senior Director of Finance & Controller |
Mr. Brian M. Culley M.A., M.B.A. | CEO, President & Director |
Ms. Brandi L. Roberts CPA, M.B.A. | Consultant |
Dr. Rami Skaliter Ph.D. | Chief Executive Officer of Cell Cure Neurosciences |
Dr. Charlotte Hubbert Ph.D. | Vice President of Corporate Development |
Dr. Harold D. Waitz | Vice President of Regulatory Affairs & Quality Control |
Ms. Jill Ann Howe | CFO & Principal Financial and Accounting Officer |
Mr. George A. Samuel III, J.D. | General Counsel & Company Secretary |
Ms. Ioana C. Hone | Director of Investor Relations |
Lineage Cell Therapeutics Inc share price today is $1.39 as on at the close of the market. Lineage Cell Therapeutics Inc share today touched a day high of $1.42 and a low of $1.35.
Lineage Cell Therapeutics Inc share touched a 52 week high of $1.42 on and a 52 week low of $0.37 on . Lineage Cell Therapeutics Inc stock price today i.e. is closed at $1.39,which is 2.11% down from its 52 week high and 280.72% up from its 52 week low.
Lineage Cell Therapeutics Inc market capitalisation is $0.00T as on .
Indian investors can start investing in Lineage Cell Therapeutics Inc (LCTX) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in Lineage Cell Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ).
Based on Lineage Cell Therapeutics Inc share’s latest price of $1.39 as on September 18, 2025 at 1:29 am IST, you will get 7.1942 shares of Lineage Cell Therapeutics Inc. Learn more about
fractional shares .
Lineage Cell Therapeutics Inc stock has given 23.85% share price returns and 20.01% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?